New Technology– category –
-
New Technology
ATSN-301: Dual AAV.SPR-MYO7A Safety and Preclinical Development
bioRxiv USA Overview Atsena Therapeutics has developed ATSN-301, a dual AAV.SPR vector system designed to treat Usher Syndrome Type 1B by reconstituting the full-length MYO7A protein. A six-month GLP toxicology study established a No Obs... -
New Technology
NPC1 Base Editing Screens: Identifying Second-Site Corrector Mutations
bioRxiv USA Overview Researchers used tiled adenine and cytosine base editing screens to identify second-site corrector mutations that rescue misfolded NPC1 proteins. The study discovered a promiscuous variant capable of correcting multi... -
New Technology
Myotropic AAV Base Editing: Muscular Dystrophy Treatment in Mice
The Journal of Clinical Investigation USA Overview Researchers have developed a single liver-sparing myotropic AAV that ameliorates muscular dystrophy in humanized mice using base editing. This approach targets muscle tissue while avoidi... -
New Technology
Amsoki-cel (OBX-115): Phase 1/2 Efficacy in ICI-Resistant Melanoma
Nature Medicine USA Overview Amsoki-cel, an engineered TIL cell therapy using regulatable membrane-bound IL-15, achieved an objective response rate (ORR) of 66.7% in a key efficacy set of patients with ICI-resistant advanced melanoma. By... -
New Technology
CAR-T Double Knockout Screen: NR4A1–SOCS3 Synergistic Pair
Nature Overview Researchers utilized a high-throughput in vivo CRISPR double-knockout (DKO) screen to identify gene pairs that enhance CAR-T cell efficacy. The NR4A1–SOCS3 DKO pair demonstrated superior antitumour potency and long-term t... -
New Technology
Human Lymphatic Organoids: Developmental Routes and Function
bioRxiv USA Overview Researchers have developed three-dimensional lymphatic organoids from human pluripotent stem cells using two distinct mesodermal routes. These organoids reconstruct functional lymphatic vessels capable of interstitia... -
New Technology
Hypoimmune Limbal Stem Cells: Off-the-Shelf LSCD Therapy Proof-of-Concept
Research Square Overview Researchers have developed hypoimmune limbal stem cells (LSCs) engineered to evade allogeneic immune recognition while maintaining stem cell identity and differentiation capacity. The approach utilizes CRISPR-Cas... -
New Technology
FASN-SREBP1 Axis: Potential Parkinson’s Therapeutic Target
bioRxiv Overview Phenotypic screening in patient-derived iPSC-dopamine neurons has identified the FASN-SREBP1 axis as a potential therapeutic target for Parkinson's disease (PD). The study demonstrates that inhibiting fatty acid synthase... -
New Technology
hiPSC Mammary Gland Organoids: Functional Model for Breast Research
bioRxiv Overview Researchers have developed a stepwise differentiation protocol to derive functional mammary gland organoids (MGOs) from human induced pluripotent stem cells (hiPSCs). These MGOs exhibit polarized bilayered epithelium and... -
New Technology
Human iPSC-derived motor neurons: Rostrocaudal identity pipeline
bioRxiv USA Overview Researchers have developed a unified pipeline to generate human induced pluripotent stem cell (iPSC)-derived motor neurons (iMNs) with defined hindbrain, cervical, and lumbar identities. By optimizing morphogen combi...